Del. Justices Reverse GSK's $57M Lupus Drug Patent Loss

Law360 (March 3, 2021, 10:05 PM EST) -- The Delaware Supreme Court reversed a trial court decision Wednesday that put pharma giant GSK on the hook for $57 million in damages over its decision to halt royalty payments on a lupus drug, ruling there were no "gaps" in its agreement with a rival that prevented the move.

In a decision authored by Chief Justice Collins J. Seitz Jr., the panel said the trial judge erred in denying GSK's motion for judgment as a matter of law on an implied covenant claim the company lost after a jury trial.

Plaintiff Drit LP accused GSK of acting in bad faith in...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!